Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma

Published:2022-11 Issue: Volume:112 Page:109110
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Cheng Chun-Chia,Ho Ai-Sheng,Peng Cheng-Liang,Chang Jungshan,Sie Zong-Lin,Wang Chih-Liang,Chen Yi-Li,Chen Cheng-Yi

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference52 articles.

1. Epidemiology of Hepatocellular Carcinoma;McGlynn;Hepatology,2021

2. Epidemiology and surveillance for hepatocellular carcinoma: New trends;Singal;J Hepatol,2020

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

4. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004

5. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells;Huang;Mol Cancer Ther,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UBAP2 contributes to radioresistance by enhancing homologous recombination through SLC27A5 ubiquitination in hepatocellular carcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. STAT3 mediates cancer stem‐like tumorsphere formation and PD‐L1 expression to contribute radioresistance in HBV‐positive hepatocellular carcinoma;Advances in Digestive Medicine;2024-04-24

3. Combined use of NK cells and radiotherapy in the treatment of solid tumors;Frontiers in Immunology;2024-01-09

4. Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing;Biomedicine & Pharmacotherapy;2023-11

5. Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma;Cancers;2023-10-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3